Difference Between Semaglutide and Tirzepatide: A Physician's Side-by-Side Comparison

Difference Between Semaglutide and Tirzepatide: A Physician's Side-by-Side Comparison

By Dr. Onikepe Adegbola, MD PhD

If you're weighing semaglutide versus tirzepatide — whether for weight loss or type 2 diabetes — you're asking one of the most common questions I hear in clinical practice. Both medications belong to the incretin family, both are injectable, and both produce meaningful results. But they are not the same drug, and the difference between semaglutide and tirzepatide matters more than most summaries let on.

Here's the honest comparison, based on trial data and what I actually see in my patients.

How the Mechanisms Differ

This is the fundamental distinction. Semaglutide is a GLP-1 receptor agonist — a single-target drug. Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it activates two incretin pathways simultaneously.

GLP-1: The Shared Pathway

Both drugs activate GLP-1 receptors in the pancreas, brain, and GI tract. This stimulates insulin secretion (when blood sugar is elevated), suppresses glucagon, slows gastric emptying, and reduces appetite through central nervous system signaling. GLP-1 receptor activation is the primary driver of both appetite suppression and glycemic control.

GIP: Tirzepatide's Extra Mechanism

GIP (glucose-dependent insulinotropic polypeptide) was historically considered a "less interesting" incretin. But tirzepatide changed that conversation. GIP receptor activation appears to enhance fat oxidation, improve insulin sensitivity in adipose tissue, and may reduce nausea by counterbalancing some of the GI effects of GLP-1 agonism.

The clinical implication: tirzepatide achieves stronger metabolic effects because it's hitting two complementary pathways. Whether this dual mechanism translates to better long-term outcomes is something we're still studying — but the short-to-medium-term data favors tirzepatide for both weight loss and A1C reduction.

Weight Loss: Head-to-Head Numbers

The SURMOUNT and SURPASS trials provide the tirzepatide data. The STEP trials provide the semaglutide data. A few direct comparisons exist, including the SURPASS-2 trial which compared tirzepatide directly to semaglutide 1 mg for diabetes.

Metric	Semaglutide 2.4 mg (Wegovy)	Tirzepatide 15 mg (Zepbound)
Average weight loss (68 weeks)	~15–16%	~22–25%
Patients losing ≥10%	~70%	~85%
Patients losing ≥20%	~32%	~55%
A1C reduction (diabetes)	~1.5–1.8%	~2.0–2.5%

These numbers matter, but context matters more. The tirzepatide trials enrolled a slightly different population, and the maximum doses differ. The honest interpretation: tirzepatide is likely more potent for weight loss on average, but individual responses vary substantially. I have patients on semaglutide who've lost 25%, and patients on tirzepatide who plateaued at 12%. Biology is personal.

Side Effect Profiles Compared

Both medications cause GI side effects. The specific patterns differ in ways that matter clinically.

Nausea

Nausea rates are roughly comparable: 40–44% for semaglutide 2.4 mg vs 24–33% for tirzepatide at various doses. There's reason to believe tirzepatide's GIP component partially buffers the nausea, though this is debated. In my practice, I see slightly less severe nausea with tirzepatide, but it's not a dramatic difference.

Diarrhea and Constipation

Semaglutide leans more toward constipation (24% in STEP trials). Tirzepatide causes more diarrhea at higher doses (17% at 15 mg). Both can go either way depending on the patient and their baseline GI function.

For patients who already struggle with constipation, tirzepatide may be the more comfortable option. For those prone to loose stools, semaglutide might be better tolerated.

Injection Site Reactions

Both are subcutaneous weekly injections. Injection site reactions are mild and infrequent with both drugs — typically less than 5% in trials.

More Serious Concerns

Both carry boxed warnings about medullary thyroid carcinoma risk (based on rodent studies — no confirmed human cases). Both can cause pancreatitis in rare cases. Both cause gallbladder events at slightly higher rates than placebo. Neither appears to increase cardiovascular risk; semaglutide has proven cardiovascular benefit in the SELECT trial, while tirzepatide's cardiovascular data is still being collected.

Supporting Your Body on Either Medication

Regardless of which medication you're on, the metabolic changes demand nutritional attention. Reduced food intake means reduced nutrient absorption. Slowed gastric emptying means your digestive system is working differently than it used to.

In my practice, I recommend a few baseline supports for patients on either semaglutide or tirzepatide:

• Protein prioritization: Aim for 1.0–1.2 g/kg of ideal body weight daily. Muscle preservation during rapid weight loss depends on this. A gut-gentle protein like GLP-1 Companion Whey Protein can help patients who struggle to eat enough solid food.
• Micronutrient coverage: A daily multivitamin formulated for GLP-1 patients — like the GLP-1 Daily Nutrition Companion — fills the gaps that reduced food volume creates.
• Digestive support: If GI symptoms are bothersome, a digestive enzyme designed for GLP-1 patients can help your body process the food you do eat more efficiently.

Cost and Access: The Practical Reality

In 2024–2025, both medications face similar access challenges:

• Brand pricing: Ozempic/Wegovy list at ~$1,000–1,300/month. Mounjaro/Zepbound list at ~$1,000–1,100/month. Actual cost depends entirely on insurance.
• Insurance coverage: Both have variable coverage. Tirzepatide has been easier to get covered for weight loss in some plans because it's newer and Eli Lilly has been more aggressive with co-pay assistance programs.
• Compounded versions: Compounded semaglutide is widely available at lower cost. Compounded tirzepatide availability has fluctuated due to FDA rulings. Check current availability with your provider.
• Oral options: Semaglutide is available as an oral tablet (Rybelsus) for diabetes. There is no oral tirzepatide currently available.

How to Choose: A Framework

There's no universally "better" medication. Here's how I help patients decide:

Consider semaglutide if:

• You want the longest safety track record (available since 2017)
• You prefer an oral option (Rybelsus)
• Your insurance covers Ozempic/Wegovy well
• You want proven cardiovascular benefit (SELECT trial)
• Compounded access matters to you (more widely available)

Consider tirzepatide if:

• Maximum weight loss is your primary goal
• You've tried semaglutide and plateaued
• You tend toward constipation (tirzepatide's GI profile may suit you better)
• You want stronger A1C reduction alongside weight loss
• Your insurance covers Mounjaro/Zepbound

In my practice, I've seen both medications transform patients' health. The best GLP-1 medication is the one you can access consistently, tolerate well, and sustain long-term. That's a conversation between you and your prescriber.

Frequently Asked Questions

Can I switch from semaglutide to tirzepatide (or vice versa)?

Yes, switching is common. Your prescriber will typically restart you at the lowest dose of the new medication to allow GI adjustment, even if you were at a high dose of the previous drug. There's no required washout period — the medications don't interact with each other.

Is tirzepatide "stronger" than semaglutide?

On average, tirzepatide produces more weight loss and greater A1C reduction in clinical trials. But "stronger" doesn't always mean "better for you." Individual responses vary significantly. Some patients respond beautifully to semaglutide and see no additional benefit from switching.

Do both medications cause the same nutritional deficiencies?

Both reduce food intake and slow digestion, which can lead to decreased absorption of B12, iron, fat-soluble vitamins, and calcium over time. The risk is proportional to how much your food intake decreases. Regular bloodwork every 3–6 months is reasonable on either drug.

Can I take both medications together?

No. There is no clinical data supporting combination use of two GLP-1 receptor agonists. The overlapping mechanisms would likely amplify side effects without proportional benefit. Choose one and optimize it with your provider.

Which one has fewer side effects?

Neither is clearly "milder." The side effect rates are broadly similar. Tirzepatide may cause slightly less nausea and slightly more diarrhea. The most practical answer is to try one, see how your body responds, and adjust from there.